TORONTO, July 12, 2013 /CNW/ - Biosign Technologies Inc. (TSXV: BIO) ("Biosign" or the "Company") announces the following:
Biosign Begins Television Advertising
The Company is pleased to announce that a new television advertising campaign will launch on Monday July 15th, 2013. Biosign will run television ads for the Pulsewave™ Health Monitor in multiple markets including St John, Fredericton & Moncton, NB as well as Toronto ON, on the Rogers TV Listings Channel. A 30-second spot will highlight the most important features of the Pulsewave™ system, including the fact that Pulsewave™ is the only approved, over-the-counter system that allows the user to see their heart beat in real time on the computer screen.
Biosign is embarking on a sustained television advertising program for Pulsewave™, initially in Canada with campaigns in the United States to follow. Rogers Digital Cable television enables the Company to target ads to specific municipalities, making it easy to control costs. The ad campaign will be evaluated on a weekly basis, tracking the amount of website traffic created as well as more traditional measures including sales and enquiries. The intention is to use the selectivity of digital cable to test various versions of each ad, in order to maximize the impact of each campaign. The first ads will push Pulsewave buyers to the Biosign web store. Later ads will test the results gained by pushing buyers to live operators as compared to website buyers.
Rogers Digital Cable reaches 3 million Eastern Canadian households, while in Western Canada the major provider is Shaw Digital Cable. Biosign intends to advertise with both providers. Through this program, Biosign expects to sell an increasing number of Pulsewave units throughout the summer and autumn of 2013.
Biosign CEO Robert Kaul commented, "The launch of our first television advertising campaign is extremely important. For the first time, Biosign has taken steps to communicate the benefits of our easy-to-use technology directly to consumers. Direct-to-consumer sales offers higher margins and the ability to control the consumer experience, which means we can deliver superior customer service. Along with our previously announced professional software integration projects (for example ClinicServer & QLINE), our direct-to-consumer program completes the Biosign go-to-market strategy."
Biosign closes private placement
On July 4th, 2013, the Company closed a private placement for 17,852,571 units of the Company (the "Units") at an average purchase price of $0.028 per Unit. Each Unit is comprised of one common share and one common share purchase warrant. Each common share purchase warrant is exercisable for a 2-year period at $0.05 per share during the first twelve months and $0.10 per share in the second twelve months. The securities issued in connection with the Offering are subject to a four-month-and-one-day hold period from the issuance date in accordance with the policies of the TSXV and applicable securities laws. No director, officer or other insider purchased any Units pursuant to the private placement. The private placement was executed under the TSX Venture Exchange's temporary relief program, which permitted reporting issuers to raise up to $500,000 under such provisions.
Former Director receives shares to satisfy indebtedness.
Pursuant to TSXV approval issued on March 12, 2013, a former director was issued 500,000 shares at a deemed value of $0.10 to settle outstanding indebtedness. These shares shall be subject to a hold period of four months plus one day from the date of issuance.
About Biosign Technologies Inc:
Biosign Technologies Inc. (TSXV: BIO) provides automated, software enabled health information solutions. Key solutions include the Pulsewave™ Health Monitor and the Healthanywhere™ Patient monitoring / self-care platform. The Company's Pulsewave™ Health Monitor solution enables Pulse data collection for cardiovascular clinical decision support, and self-care, while its Healthanywhere™ solution offers industry-leading remote patient monitoring, and patient centred care management . The Company also offers a number of cardiovascular screening programs for consumers under its Heart Friendly™ brand, including Heart Friendly™ Practice, Heart Friendly™ Dentist, and Heart Friendly™ Fitness. For more information on Biosign, please visit www.biosign.com
This release contains forward-looking statements. Forward-looking statements, without limitation, may contain the words believes, expects, anticipates, estimates, intends, plans, or similar expressions. Forward-looking statements are not guarantees of future performance. They involve risks, uncertainties and assumptions and Biosign's actual results could differ materially from those anticipated. Forward looking statements are based on the opinions and estimates of management at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. In the context of any forward-looking information please refer to risk factors detailed in, as well as other information contained in the company's filings with Canadian securities regulators (www.sedar.com).
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
SOURCE: Biosign Technologies Inc.
For further information:
Chief Executive Officer
Biosign Technologies Inc
Phone: (416) 218-9800 ext. 201
Email: [email protected]